Progress in drug development often hides inside failures. A therapy that fails in one clinical trial can provide critical scientific learnings. One company leveraged insights from a failed study to redesign a subsequent trial, which was successful and led to the drug's approval.

Uniquity Bio, a 35-person firm, runs three Phase 2 trials concurrently—a resource-intensive strategy. This is possible because substantial private funding (from Blackstone) allows them to focus on clinical advancement rather than constant fundraising, de-risking an aggressive, multi-pronged approach.

Coya Therapeutics' vision is to make diseases like ALS "livable" by completely stopping their progression. This ambitious goal stems from a small investigator-initiated trial where patients showed no disease progression over six months, a period where a significant decline is typically expected, reframing the therapeutic benchmark.

Coya Therapeutics is pursuing a novel therapeutic goal for ALS: making the condition "livable" by stopping its progression. Instead of aiming for a cure or reversing existing damage, their strategy focuses on preserving a patient's current motor function, which would represent a significant breakthrough in managing the neurodegenerative disease.

For a small biotech, demonstrating that a drug is both clinically active on its own and well-tolerated is the most critical step. This de-risks the asset and opens the door to lucrative combination therapy partnerships with large pharma companies, as it minimizes the risk of combined toxicity killing the trial.

The process of testing drugs in humans—clinical development—is a massive, under-studied bottleneck, accounting for 70% of drug development costs. Despite its importance, there is surprisingly little public knowledge, academic research, or even basic documentation on how to improve this crucial stage.

For a platform company with wide-ranging technology, the key early struggle is focusing. It is critical to prioritize a single program to generate near-term data and change the cost of capital before realizing the platform's full potential.

The fundamental purpose of any biotech company is to leverage a novel technology or insight that increases the probability of clinical trial success. This reframes the mission away from just "cool science" to having a core thesis for beating the industry's dismal odds of getting a drug to market.

Biotech leaders must stop viewing commercialization as a post-approval task. The critical window is Phase 2 clinical trials. By embedding patient journey and quality of life insights into secondary endpoints, companies can build a compelling value proposition for payers and physicians. Waiting until Phase 3 is too late.